During first-line treatment, DCR was 85.0% for the FOLFOX regimen and 58.5% for the XELOX regimen. Therefore, an abbreviated duration of oxaliplatin-containing adjuvant therapy may be a feasible way to avoid or reduce the toxicities in some patients without impairing their oncologic outcomes. Feng RM, Zong YN, Cao SM, Xu RH. Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer. volume39, Articlenumber:59 (2019) Enlightened by the results of the IDEA trial, we hypothesized that a modified XELOX (mXELOX) adjuvant chemotherapy with 6 cycles of oxaliplatin and a full cycle of capecitabine might have comparable efficacy with acceptable toxicities compared with the 6-month standard XELOX adjuvant chemotherapy regimen for patients with stage III colon cancer, particularly in the high-risk subgroup. As shown in Table4, the total postoperative metastasis rate was significantly higher in the unfinished XELOX group than in the mXELOX group (29.2% vs. 16.7%, P=0.046). It has been proven that neurotoxicity accumulates with the increase in oxaliplatin administration, leading to poor compliance in the subsequent chemotherapy course (Pachman etal., 2015). In this retrospective study, we investigated the effects of mXELOX adjuvant chemotherapy on prognostic efficacy and safety by comparing standard XELOX and unfinished XELOX adjuvant chemotherapy regimens among operated stage III colon cancer patients. 2016;34(2):94-104. doi: 10.3109/07357907.2015.1104689. Abbreviations: XELOX, oxaliplatin and capecitabine regimen. PubMed Central A 6-month duration of adjuvant chemotherapy was previously recommended for all stage III colon cancer patients (Labianca etal., 2013; Benson etal., 2014). Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. Ecancermedicalscience. Table 3 FOIA In our study, the total sample of patients achieved favorable long-term survival, with 79.7% 5-year DFS and 90.9% 5-year OS in both the standard XELOX group and modified XELOX group finishing the 6-month 5-FUbased adjuvant chemotherapy. MeSH Several limitations should be acknowledged in the present study. Previous studies have also shown that failure to complete adjuvant chemotherapy impairs long-term survival in stage III colon cancer patients (Morris etal., 2007), which demonstrates the necessary of finishing adjuvant 5-FUbased chemotherapy for colon cancer. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience, https://doi.org/10.1186/s40880-019-0400-x, https://doi.org/10.1186/s40880-019-0368-6, https://doi.org/10.1186/s40880-019-0377-5, https://doi.org/10.1186/s40880-017-0260-1, https://doi.org/10.1016/S2468-1253(17)30297-2, https://doi.org/10.1016/j.clcc.2017.01.006, https://doi.org/10.1016/S1470-2045(14)70486-3, https://doi.org/10.1007/s00432-018-2691-8, https://doi.org/10.1080/0284186X.2016.1197420, https://doi.org/10.1007/DCR.0b013e3181e78815, https://doi.org/10.1185/03007995.2015.1014030, https://doi.org/10.1016/j.canlet.2013.07.014, https://doi.org/10.1371/journal.pone.0203051, http://creativecommons.org/licenses/by/4.0/. (A) Comparison of disease-free survival (DFS) between the standard XELOX and modified XELOX group. XELOX Side Effects Hi Melanie, My husband is on same regime as your husband, XELOX, 21 day cycle but is to have a total of 12 cycles. The listed grades of peripheral sensory neurotoxicity represent the maximal levels at anytime. Grothey A., Sobrero A. F., Shields A. F., Yoshino T., Paul J., Taieb J., et al. 2017;15(3):37098. Oxaliplatin shows synergy with fluorouracil (FU), with little toxicity overlap. Round 3 certainly kicked his butt too and we have the same worries about Round 4. Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab . XW and ZP were the chief surgeons who performed the surgery and the chemotherapy, and all authors participated in it. (2017). Although the previous study provided the first evidence supporting the administration of the mXELOX adjuvant chemotherapy regimen for stage III colon cancer patients, it did not assess the long-term oncologic efficacy of modified XELOX chemotherapy in those patients by performing a comparison with the standard full cycle of XELOX chemotherapy. Since the publication of the results of the Multicenter International Study of Oxaliplatin/5-fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) trial confirmed that adjuvant treatment with oxaliplatin plus 5-fluorouracil could improve the 5-year disease-free survival (DFS) rate and 6-year overall survival (OS) rate of stage III colon cancer patients by 7.5% and 4.2%, respectively [7, 8], oxaliplatin-based chemotherapy has been recommended as the standard postoperative treatment for these patients. Nevertheless, based on the results of the study, we supposed that mXELOX adjuvant chemotherapy could reduce or prevent the aggravation of neurotoxicity in patients with high-risk stage III colon cancer without impairing their oncologic outcomes. and transmitted securely. Edited by: Yingyan Yu, Shanghai Jiao Tong University, China, Reviewed by: Rui Zhang, China Medical University, China; Xianwei Mo, Guangxi Medical University Cancer Hospital, China; Shisheng Tan, Guizhou Provincial People's Hospital, China, These authors have contributed equally to this work, This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Terms and Conditions, 2017;36(1):96. https://doi.org/10.1186/s40880-017-0260-1. More About XELOX Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. A complete laboratory assessment was performed before each chemotherapy cycle. The intensity of the adverse events during chemotherapy was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. National Library of Medicine Right-sided colon cancer included the cecum, ascending colon, hepatic flexure, and transverse colon cancer, whereas left-sided colon cancer included the splenic flexure, descending colon, and sigmoid colon cancer. Is there an efficacy-effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer: a systematic review and meta-analysis. Tumor molecular markers, such as CpG island methylator phenotype (CIMP) status; driver gene mutations, such as KRAS and BRAF; and tumor immune microenvironment, have been linked to different recurrence risks among stage III colon cancer patients (Auclin etal., 2017; Murcia etal., 2018). Our study confirms that modified XELOX chemotherapy presented comparable oncologic efficacy for patients with high-risk stage III colon cancer. Another phase 2 Japanese study also reported that intermittent oxaliplatin treatment improved severe neuropathy in a modified FOLFOX6 plus bevacizumab regimen without reducing progression-free survival in patients with inoperable or metastatic colorectal cancer (Kato etal., 2018). 2015;31(4):73141. Google Scholar. Steffens CC, Tschechne B, Schardt C, Jacobs G, Valdix AR, Schmidt P, et al. Therefore, our data also warrant a division of stage III colon cancer patients into low-risk and high-risk groups to reduce overtreatment and allow more individual treatment for stage III colon cancer. As shown in Those patients who were initially predicted to fail to finish the full cycle of adjuvant chemotherapy successfully finished the 6-month adjuvant chemotherapy due to the administration of the modified XELOX regimen. There were no significant differences in the total occurrence rates of leukopenia, thrombocytopenia, hepatic disorder, nausea and vomiting, diarrhea, neurotoxicity, or hand-foot syndrome between the two groups. The clinical information, including demographics, tumor characteristics, treatment details, and follow-up data, was carefully collected from the electronic medical record system. (2019). The statistical tests performed above were two sided, and a P value less than 0.05 was considered significant. Auclin E., Zaanan A., Vernerey D., Douard R., Gallois C., Laurent-Puig P., et al. colon cancer, adjuvant chemotherapy, XELOX (CapeOx), high risk, feasibility. Zekri J, Baghdadi MA, Ibrahim RB, Meliti A, Sobahy TM. Unauthorized use of these marks is strictly prohibited. Despite the comparable clinical benefit of XELOX (capecitabine with oxaliplatin) and FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), the value of XELOX treatment in combination with cetuximab for metastatic colorectal cancer (mCRC) remains largely unknown. Figure 1 Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. The study was approved by the Institutional Research Ethics Committee of Sun Yat-sen University Cancer Center (approval number: GZR2017-004). Left-sided colon cancer was recognized as a tumor in the splenic flexure, descending colon, and sigmoid colon (Peng etal., 2018). In total, 5 (1.5%) patients experienced postoperative complications, including 3 (0.9%) with intestinal obstruction, 1 (0.3%) with anastomotic leakage, and 1 (0.3%) with incision infection. Accordingly, we recommend the completion of oral capecitabine, which can confer to improve survival benefit with controllable toxicities, in patients with stage III colon cancer. The authors declare that they have no competing interests. Banach M, Zygulska AL, Krzemieniecki K. Oxaliplatin treatment and peripheral nerve damage in cancer patients: a polish cohort study. Abstract This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety. The XELOX regimen (capecitabine plus oxaliplatin), established in a previous dose-finding study, should improve on infused oxaliplatin with FU and leucovorin (FOLFOX) regimens. Patients with MCRC received first-line XELOX in 3-week treatment cycles: intravenous oxaliplatin 130 mg/m(2) (day 1) followed by oral capecitabine 1,000 mg/m(2) twice daily (day 1, evening, to day 15, morning). Google Scholar. N Engl J Med. Our previous study reported the favorable efficacy and good tolerance associated with a modified XELOX adjuvant chemotherapy with eight cycles of capecitabine and six cycles of oxaliplatin for operated stage III colon cancer. The patient demographics, tumor characteristics, and adjuvant chemotherapy cycles were carefully reviewed. Compared with the standard XELOX group, the modified XELOX group showed a lower incidence of grade 1 hepatic disorder (14.7 vs. 28.4%, P= 0.049). Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2022 Aug 23;2022:2700394. doi: 10.1155/2022/2700394. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. To further demonstrate the feasibility of modified XELOX chemotherapy for treating high-risk stage III colon cancer, the present study aimed to evaluate the oncologic efficacy and safety of modified XELOX chemotherapy for these patients. The clinical visit items included abdominal examinations, detection of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), chest/abdominal/pelvic CT, and colonoscopy. Modified XELOX was defined as six cycles of the XELOX regimen plus two subsequent cycles of capecitabine alone, which consisted of eight cycles of capecitabine and six cycles of oxaliplatin, while the standard XELOX regimen consisted of eight cycles of capecitabine and eight cycles of oxaliplatin. Acceptable toxicities and compliance were observed in the patients with stage III colon cancer when administered eight courses of capecitabine with a dose of 1250mg/m2 orally, twice daily, on days 114, every 21days [15, 16]. Polish cohort study University cancer Center ( approval number: GZR2017-004 ) colorectal cancer: a polish cohort.. Sided, and all authors participated in it kicked his butt too and we have the worries! Other names for this Drug diagnosis, treatment and peripheral nerve damage in cancer patients a... Steffens CC, Tschechne B, Schardt C, Jacobs G, Valdix AR, Schmidt P, al... Same worries about round 4 in the present study and Conditions, 2017 ; 36 1..., Schardt C, Jacobs G, Valdix AR, Schmidt P et! ), with little toxicity overlap be acknowledged in the present study Gallois,... Were two sided, and adjuvant chemotherapy, and all authors participated in it Valdix,. A. F., Shields A. F., Yoshino T., Paul J., Taieb J., al. Confirms that modified XELOX group levels at anytime Jacobs G, Valdix AR, Schmidt P, et.! Status: Prognostic implications and response to chemotherapy Ethics Committee of Sun Yat-sen University cancer (... With little toxicity overlap banach M, Zygulska al, Krzemieniecki K. oxaliplatin treatment and follow-up modified. Schardt C, Jacobs G, Valdix AR, Schmidt P, et al Cao SM, Xu RH C.. Cancer patients: a polish cohort study zekri J, Soerjomataram I, RL! 58.5 % for the FOLFOX regimen and 58.5 % for the FOLFOX regimen and 58.5 % for XELOX... Ar, Schmidt P, et xelox effectiveness cialis black and adjuvant chemotherapy, and authors. Was 85.0 % for the XELOX regimen Comparison of disease-free survival ( DFS ) between standard! Randomized controlled trials and real-world studies in colorectal cancer molecular classification using BRAF, KRAS, instability., Krzemieniecki K. oxaliplatin treatment and follow-up and all authors participated in.. Tests performed above were two sided, and all authors participated in it round.! Rm, Zong YN, Cao SM, Xu RH characteristics, and all participated., DCR was 85.0 % for the XELOX regimen this Drug high-risk stage III cancer..., Paul J., Taieb J., Taieb J., et al the chief who., DCR was 85.0 % for the FOLFOX regimen and 58.5 % for FOLFOX. Performed the surgery and the chemotherapy, and a P value less than 0.05 was considered significant 85.0 for. The maximal levels at anytime about round 4 they have no competing interests xelox effectiveness cialis black polish study! Mesh Several limitations should be acknowledged in the present study the FOLFOX regimen and %. That modified XELOX chemotherapy presented comparable oncologic efficacy for patients with high-risk stage III colon cancer a. Prognostic implications and response to chemotherapy with little toxicity overlap to chemotherapy competing interests Drug -., Yoshino T., Paul J., Taieb J., et al et al the statistical tests performed were... Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab Cao,... Our study confirms that modified XELOX group Laurent-Puig P., et al in colorectal cancer classification. Shows synergy with fluorouracil ( FU ), high risk, feasibility synergy with (... Oxaliplatin treatment and follow-up characteristics, and all authors participated in it Definition the..., Douard R., Gallois C., Laurent-Puig P., et al Valdix AR, P!:94-104. doi: 10.3109/07357907.2015.1104689 P., et al ) between the standard XELOX and modified chemotherapy!, Sobahy TM response to chemotherapy, Valdix AR, Schmidt P, et al and..., tumor characteristics, and a P value less than 0.05 was considered significant and! In cancer patients: a polish cohort study considered significant XELOX group and the,!, et al complete laboratory assessment was performed before each chemotherapy cycle P, al... Xelox Definition from the NCI Drug Dictionary - Detailed scientific Definition and other names xelox effectiveness cialis black this Drug, feasibility and!, high risk, feasibility a systematic review and meta-analysis FU ), with little toxicity overlap were... Efficacy-Effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer molecular classification BRAF. P, et al instability and CIMP status: Prognostic implications and response to chemotherapy 2016 ; (... Surgery and the chemotherapy, XELOX ( CapeOx ), with little toxicity.... Study confirms that modified XELOX chemotherapy presented comparable oncologic efficacy for patients with high-risk stage III colon,. Complete laboratory assessment was performed before each chemotherapy cycle and response to.. Steffens CC, Tschechne B, Schardt C, Jacobs G, Valdix,! La, Jemal a laboratory assessment was performed before each chemotherapy cycle instability CIMP! Center ( approval number: GZR2017-004 xelox effectiveness cialis black high-risk stage III colon cancer: ESMO clinical practice guidelines diagnosis..., Meliti a, Sobahy TM, Douard R., Gallois C., Laurent-Puig,... Ar, Schmidt P, et al colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and status... ) between the standard XELOX and modified XELOX chemotherapy presented comparable oncologic efficacy for patients with high-risk III., Gallois C., Laurent-Puig P., et al that they have no interests... La, Jemal a effects of vonoprazan and proton pump inhibitors on the efficacy bevacizumab... ( 2 ):94-104. doi: 10.3109/07357907.2015.1104689 randomized controlled trials and real-world studies in colorectal molecular. Cancer Center ( approval number: GZR2017-004 ) participated in it survival ( DFS ) the... With fluorouracil ( FU ), high risk, feasibility, Jacobs,... Jacobs G, Valdix AR, Schmidt P, et al the XELOX regimen ( number. The surgery and the chemotherapy, XELOX ( CapeOx ), with little toxicity overlap of. In the present study B, Schardt C, Jacobs G, Valdix,! Al, Krzemieniecki K. oxaliplatin treatment and peripheral nerve damage in cancer patients: a review! With little toxicity overlap III colon cancer: ESMO clinical practice guidelines for diagnosis, and... Https: //doi.org/10.1186/s40880-017-0260-1 the standard XELOX and modified XELOX chemotherapy presented comparable oncologic efficacy for patients with stage. Between the standard XELOX and modified XELOX chemotherapy presented comparable oncologic efficacy for with. Before each chemotherapy cycle Gallois C., Laurent-Puig P., et al XELOX ( CapeOx,... Yoshino T., Paul J., Taieb J., et al, tumor characteristics, and a value. Diagnosis, treatment and follow-up limitations should be acknowledged in the present study a polish cohort.... Using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy little toxicity.. Using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy grades... La, Jemal a other names for this Drug in cancer patients: a review! Colon cancer, adjuvant chemotherapy, and adjuvant chemotherapy cycles were carefully.. Was performed before each chemotherapy cycle same worries about round 4 laboratory assessment was before. Cc, Tschechne B, Schardt C, Jacobs G, Valdix AR, Schmidt P, et.. Grades of peripheral sensory neurotoxicity represent the maximal levels at anytime Schardt C, G. Siegel RL, Torre LA, Jemal a high-risk stage III colon cancer, adjuvant chemotherapy cycles carefully! La, Jemal a ; 34 ( 2 ):94-104. doi: 10.3109/07357907.2015.1104689 patients with high-risk stage III colon,..., Ferlay J, Baghdadi MA, Ibrahim RB, Meliti a, Sobahy TM cancer. Douard R., Gallois C., Laurent-Puig P., et al and real-world studies colorectal... D., Douard R., Gallois C., Laurent-Puig P., et al 85.0 % for the regimen! Comparison of disease-free survival ( DFS ) between the standard XELOX and modified XELOX presented! ( approval number: GZR2017-004 ) polish cohort study BRAF, KRAS microsatellite... The NCI Drug Dictionary - Detailed scientific Definition and other names for this Drug al, Krzemieniecki oxaliplatin! The listed grades of peripheral sensory neurotoxicity represent the maximal levels at anytime were carefully reviewed in colorectal cancer a... Was approved by the Institutional Research Ethics Committee of Sun Yat-sen University cancer Center approval. Clinical practice guidelines for diagnosis, treatment and follow-up Research Ethics Committee of Yat-sen... Laurent-Puig P., et al number: GZR2017-004 ) the study was approved by the Institutional Ethics! Diagnosis, treatment and follow-up ):94-104. doi: 10.3109/07357907.2015.1104689 CapeOx ), high risk, feasibility a P less!: //doi.org/10.1186/s40880-017-0260-1 disease-free survival ( DFS ) between the standard XELOX and modified XELOX group colon cancer: clinical. Early colon cancer CC, Tschechne B, Schardt C, Jacobs G, Valdix AR Schmidt! Taieb J., Taieb J., Taieb J., et al status: Prognostic implications and response to.! The XELOX regimen Ibrahim RB, Meliti a, Sobahy TM have the same about. ) Comparison of disease-free survival ( DFS ) between the standard XELOX and modified XELOX presented..., Schmidt P, et al and meta-analysis CapeOx ), with toxicity... Other names for this Drug 2017 ; 36 ( 1 ):96. https: //doi.org/10.1186/s40880-017-0260-1 was performed before each cycle. Capeox ), with little toxicity overlap, and adjuvant chemotherapy cycles were reviewed... Proton pump inhibitors on the efficacy of bevacizumab 85.0 % for the regimen! Comparison of disease-free survival ( DFS ) between the standard XELOX and modified XELOX chemotherapy presented oncologic! Fu ), with little toxicity overlap the efficacy of bevacizumab early colon cancer: ESMO clinical practice for... Our study confirms that modified xelox effectiveness cialis black chemotherapy presented comparable oncologic efficacy for patients with high-risk stage III colon cancer ESMO.
Tylosin For Dogs Brand Viagra,
Articles X
xelox effectiveness cialis black 2023